雅本化学股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 2025 年 1 月 24 日，雅本化学股份有限公司（以下简称"公司"）第五届 董事会第二十三次（临时）会议和第五届监事会第二十二次（临时）会议审议 通过了《关于公司为子公司提供担保及子公司互相担保的议案》。为满足子公 司的经营发展需要，公司同意为全资子公司南通雅本化学有限公司（以下简称 "南通雅本"）办理银行授信等业务提供担保。具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网上披露的《关于公司为子公司提供担保及子公司互相担保 的公告》（公告编号：2025-008）。2025 年 2 月 24 日，公司 2025 年第一次临 时股东大会审议通过了上述议案。 证券代码：300261 证券简称：雅本化学 公告编号：2026-011 2025 年 6 月 16 日，公司第六届董事会第四次（临时）会议和第六届监事 会第四次（临时）会议审议通过了《关于全资子公司向银行申请项目贷款并由 公司提供担保的议案》，公司同意为南通雅本申请银行项目贷款提 ...

Core Viewpoint - The company, Yabont Chemical (300261.SZ), clarifies that it does not produce niacinamide and focuses on CDMO services for innovative pharmaceuticals and agricultural intermediates [1] Group 1 - The company's NMN-related business is operating normally [1] - The overseas subsidiary organizes and commissions compliant foreign manufacturers for production [1] - Products are sold through cross-border e-commerce platforms such as JD International and Pinduoduo [1]

Core Viewpoint - The company, Yabao Chemical (300261.SZ), clarifies that it does not produce niacinamide and focuses on CDMO services for innovative pharmaceuticals and agricultural intermediates [1] Group 1: Business Operations - The company's NMN-related business is operating normally, organized by its overseas subsidiary [1] - Production is entrusted to compliant overseas manufacturers [1] - Sales are conducted through cross-border e-commerce platforms such as JD International and Pinduoduo [1]

经济观察网近7天(2026年02月05日至02月11日)，雅本化学（300261）的热点主要集中在汇率风险管理 举措和业务布局进展。根据上海证券报的报道，2026年开年以来，包括雅本化学在内的超过40家上市公 司密集发布外汇套期保值业务公告，以应对人民币汇率波动风险，公司计划开展金额不超过6000万美元 的外汇衍生品套期保值业务。此外，02月05日，雅本化学在投资者互动平台回复称，公司已布局若干农 药原药项目，将根据市场需求与客户订单合理安排生产，这回应了农药行业政策调整带来的潜在机遇。 股价方面，雅本化学在近7天内呈现波动走势。根据内部数据库，02月09日股价大幅上涨，收盘价报 7.50元，单日涨跌幅为6.08%，成交金额达3.48亿元；但02月10日回调至7.28元，跌2.93%，02月11日进 一步微跌0.27%至7.26元。整体来看，近5日涨跌幅为2.25%，区间振幅达11.52%。资金流向显示，02月 11日主力资金净流出706.92万元，散户资金呈净流入态势。技术面上，当前股价接近20日移动平均线 (7.28元)，布林带指标显示压力位在7.72元，支撑位在6.84元。 以上内容基于公开资料整理，不 ...

证券代码：300261 证券简称：雅本化学 公告编号：2026-010 雅本化学股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 2025 年 1 月 24 日，雅本化学股份有限公司（以下简称"公司"）第五届 董事会第二十三次（临时）会议和第五届监事会第二十二次（临时）会议审议 通过了《关于公司为子公司提供担保及子公司互相担保的议案》。为满足子公 司的经营发展需要，公司同意为全资子公司兰州雅本精细化工有限公司（以下 简称"兰雅精化"）办理银行授信等业务提供担保。具体内容详见公司于 2025 年 1 月 25 日在巨潮资讯网上披露的《关于公司为子公司提供担保及子公司互相 担保的公告》（公告编号：2025-008）。2025 年 2 月 24 日，公司 2025 年第一 次临时股东大会审议通过了上述议案。 二、担保的进展情况 为满足日常经营发展需要，兰雅精化向兰州银行股份有限公司福鑫支行 （以下简称"兰州银行福鑫支行"）申请了不超过人民币 500 万元的授信额度。 近日，公司与兰州银行福鑫支行签署《最高额连 ...

Market Performance - The agricultural chemical sector increased by 0.17% on February 4, with Jinzhengdai leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] Individual Stock Performance - Jinzhengdai (002470) closed at 2.03, up 5.73% with a trading volume of 1.79 million shares and a transaction value of 361 million yuan [1] - Hongtaiyang (000525) closed at 5.89, up 4.43% with a trading volume of 393,200 shares and a transaction value of 233 million yuan [1] - Hongda Co. (600331) closed at 16.43, up 2.88% with a trading volume of 761,800 shares and a transaction value of 1.236 billion yuan [1] - Yabeng Chemical (300261) closed at 7.10, up 2.60% with a trading volume of 285,200 shares and a transaction value of 203 million yuan [1] - Other notable stocks include Chitianhua (600227), Yuntu Holdings (002539), and Sichuan Meifeng (000731), all showing positive gains [1] Capital Flow Analysis - The agricultural chemical sector experienced a net outflow of 192 million yuan from institutional investors, while retail investors saw a net inflow of 212 million yuan [2] - The overall net outflow from retail investors was 20.05 million yuan [2] Detailed Capital Flow for Selected Stocks - Salt Lake Co. (000792) had a net inflow of 89.5 million yuan from institutional investors, while retail investors experienced a net outflow of 54.6 million yuan [3] - Jinzhengdai (002470) saw a net inflow of 35.3 million yuan from institutional investors, with retail investors facing a net outflow of 24.0 million yuan [3] - Other stocks like Yuntu Holdings (002539) and Hongtaiyang (000525) also showed varying capital flows, with significant net outflows from retail investors [3]

Core Viewpoint - Yabao Chemical's stock experienced a slight decline of 0.81% on January 30, with a trading volume of 198 million yuan, indicating a mixed market sentiment towards the company [1]. Financing Summary - On January 30, Yabao Chemical had a financing buy amount of 11.56 million yuan and a financing repayment of 12.03 million yuan, resulting in a net financing buy of -467,800 yuan [1]. - As of January 30, the total financing and securities lending balance for Yabao Chemical was 273 million yuan, with the financing balance at 272 million yuan, accounting for 3.83% of the circulating market value, which is above the 80th percentile of the past year [1]. - The securities lending aspect showed no shares were repaid or sold on January 30, with a remaining quantity of 50,400 shares and a securities lending balance of 372,000 yuan, which is below the 20th percentile of the past year [1]. Business Performance - As of January 9, Yabao Chemical had 52,300 shareholders, a decrease of 1.56% from the previous period, while the average circulating shares per person increased by 1.59% to 18,025 shares [2]. - For the period from January to September 2025, Yabao Chemical reported a revenue of 996 million yuan, representing a year-on-year growth of 6.00%, while the net profit attributable to the parent company was -6.92 million yuan, showing a significant year-on-year improvement of 87.81% [2]. Dividend and Shareholding - Since its A-share listing, Yabao Chemical has distributed a total of 478 million yuan in dividends, with 95.9 million yuan distributed over the past three years [3]. - As of September 30, 2025, among the top ten circulating shareholders, the Southern CSI 1000 ETF (512100) emerged as the seventh largest shareholder with 6.1681 million shares, marking its entry as a new shareholder, while Hong Kong Central Clearing Limited exited the top ten list [3].

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining attention in the global health industry for its potential in anti-aging, DNA repair, and metabolic regulation, with significant advancements in regulatory approval and market potential expected by 2025 [1][2]. Industry Development - The NMN industry has evolved from laboratory research to commercial application, with major markets like the US, Japan, Canada, and Australia recognizing its legal status through various regulatory pathways [1][2]. - China is currently the largest producer of NMN raw materials, with leading companies building competitive barriers through technological innovation and industry chain layout [2]. NMN Definition and Function - NMN is a direct precursor of NAD+ (Nicotinamide Adenine Dinucleotide), crucial for delaying aging and enhancing physiological functions [3][4]. - Supplementing NMN can quickly elevate NAD+ levels in the body, playing a vital role in anti-aging, cardiovascular health, and metabolic improvement [4][6]. Synthesis Pathways - NMN supplementation shows significant advantages in NAD+ synthesis pathways compared to other precursors, with the highest conversion efficiency and no known adverse reactions [6][7]. Natural Sources and Supplementation - Natural food sources of NMN are limited, making NMN supplements, which can provide up to 300 times the dietary intake, more effective for achieving beneficial doses [8]. Synthesis Technology - The NMN synthesis process has shifted from chemical methods to fully enzymatic methods, focusing on high purity, safety, and environmental sustainability [10][12]. - Leading companies are innovating in full enzymatic synthesis and patenting technologies to create competitive advantages [12]. Market Trends and Demand - The aging population and increasing anti-aging awareness among younger demographics are driving demand for NMN products, with the market expected to grow significantly [19][21]. - The NMN market in China is projected to exceed 3 billion yuan by 2025, with applications expanding beyond health supplements and cosmetics into areas like pet nutrition and agricultural technology [28][24]. Application Areas - NMN is primarily used in health supplements (90% market share) and cosmetics (10-20% market share), with potential future applications in pet nutrition, medical health, and agricultural technology [24][28]. - The Chinese health supplement market is expected to surpass 430 billion yuan by 2025, indicating substantial growth potential for NMN products [40]. Sales Channels - NMN products are mainly sold through cross-border e-commerce and private channels, with cross-border platforms accounting for 60-70% of market share [35]. Regulatory Environment - The regulatory landscape for NMN is evolving, with significant progress in China towards legalizing NMN as a health supplement, which could reshape the market dynamics [17][61]. - The "blue hat" certification for health supplements in China represents the highest standard for product safety and compliance, which could significantly impact market structure if achieved [37]. Challenges and Opportunities - The NMN industry faces challenges such as exaggerated claims, lack of consumer awareness, and technological iterations, necessitating a focus on compliance and innovation to unlock market potential [61][63]. - Companies are encouraged to innovate their business models and extend their value chains to enhance competitiveness and market presence [66].

Core Viewpoint - Yabont Chemical (300261.SZ) has disclosed its performance forecast for the year 2025, expecting a net loss attributable to shareholders of between 140 million yuan and 160 million yuan, with a net loss excluding non-recurring gains and losses estimated between 128 million yuan and 148 million yuan [1] Financial Summary - The company anticipates a net loss of 140 million to 160 million yuan for 2025 [1] - The expected net loss after excluding non-recurring items is projected to be between 128 million and 148 million yuan [1]

Core Viewpoint - The company, Yabao Chemical, anticipates a significant net loss for the year 2025, with projected losses ranging from 140 million to 160 million RMB, and a net profit loss excluding non-recurring items estimated between 128 million and 148 million RMB [1] Group 1: Financial Performance - The company's pesticide business has shown steady revenue growth; however, increased market competition for key products and ongoing capacity ramp-up for some innovative products have resulted in a low overall gross margin [1] - The pharmaceutical segment has established a partnership with key pharmaceutical clients, but due to the short duration of collaboration, the related research and development and capacity support have not yet positively impacted the company's performance [1] - The company expects to incur a non-recurring loss of approximately 12 million RMB for 2025, primarily due to fair value changes [1] Group 2: Strategic Developments - The company is optimizing the strategic positioning of its pharmaceutical business bases, leading to short-term performance fluctuations due to resource integration and business layout adjustments [1] - The company is deepening its strategic layout for innovative pharmaceuticals and pesticides, which involves necessary and prudent cost investments that may pressure cash flow and profits in the short term but are expected to enhance long-term technical strength and market competitiveness [1] - A subsidiary engaged in bio-waste resource treatment has faced challenges due to industry cycle fluctuations and market competition, leading to a contraction in project scale and an anticipated provision for asset impairment related to accounts receivable [1] Group 3: Impairment and Valuation - The company will conduct impairment testing on goodwill assets in accordance with regulatory requirements, expecting to recognize goodwill impairment [1]